Form 8-K · Current report
Sandisk 8-K, filed Sep 16, 2026
- Filed
- CIK
- 0002023554
- Accession no.
- 0001628280-26-062267
Summary
Sandisk's Compensation and Talent Committee approved compensation adjustments for Chief Technology Officer Alper Ilkbahar and Chief Legal Officer Bernard Shek, effective October 1, 2026, while the base salaries and short-term incentive targets of CEO David Goeckeler and CFO Luis Visoso were left unchanged.
Key points
- Alper Ilkbahar, Sandisk's Chief Technology Officer, receives an adjusted annual base salary of $755,000 and a 100% short-term incentive target.
- Bernard Shek, Sandisk's Chief Legal Officer, receives an adjusted annual base salary of $618,000 and a 100% short-term incentive target.
- CEO David Goeckeler's annual base salary of $1,300,000 and 200% STI target are unchanged, as are CFO Luis Visoso's 150% STI target and Ilkbahar's STI target.
- The adjustments were approved by the Board's Compensation and Talent Committee and take effect October 1, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, following an annual review of the compensation levels of the executive officers of Sandisk Corporation (the “Company”), the Compensation and Talent Committee of the Board of Directors of the Company approved compensation adjustments for Alper Ilkbahar, the Company’s Chief Technology Officer, and Bernard Shek, the Company’s Chief Legal Officer, each effective as of October 1, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.